Performance | China National Pharmaceutical Group's profit increased by 1.5% last year

SighingCashier · 2026-03-23T00:31:26+00:00

China National Pharmaceutical Group published its financial results for the year ended December 31, 2025, with net profit attributable to shareholders of 7.155 billion yuan, up 1.5% year-over-year, while revenue declined 1.6% to 575.168 billion yuan. The company will promote high-quality development in 2026, focusing on business transformation and compliance risk management, while strengthening its industry leadership position.

SighingCashier

2026-03-23 00:31:26

Abstract generation in progress

China National Pharmaceutical Group (01099) announced its annual results for the year ending December 2025. Shareholders’ profit attributable to the company was RMB 7.155 billion, an increase of 1.5% year-on-year. Earnings per share were RMB 2.29, with a final dividend of RMB 0.69 per share.

During the period, revenue was RMB 575.168 billion, down 1.6% year-on-year, mainly due to declines in the group’s pharmaceutical distribution, medical device distribution, and other business segment revenues.

China National Pharmaceutical Group stated that 2026 marks the beginning of the “14th Five-Year Plan” layout. The group will adhere to serving national strategies and people’s livelihood as its fundamental purpose, unwaveringly promoting high-quality development. In the new year, the group will continue to scientifically assess industry policies and competitive landscape, focus on new development stages, concentrate on core responsibilities and main businesses, deepen business transformation and innovation-driven growth, and continuously strengthen lean operations and compliance risk management to ensure stable and orderly business development, further consolidating its leading position in the industry.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes